ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Trilaciclib, Cemiplimab & GU Updates"
Episode Synopsis
Topics covered:
1. Trilaciclib's approval to minimize bone marrow suppression
2. Cemiplimab's approval for mNSLC with high PD-L1 expression
3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma
4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer
5. More of the same with lenvatinib + pembrolizumab in mRCC
1. Trilaciclib's approval to minimize bone marrow suppression
2. Cemiplimab's approval for mNSLC with high PD-L1 expression
3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma
4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer
5. More of the same with lenvatinib + pembrolizumab in mRCC
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust